Alzheimers Disease Clinical Trial
Official title:
International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US
This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
| Terminated |
NCT02565511 -
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01993836 -
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
|
Phase 4 | |
| Completed |
NCT00448799 -
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04639050 -
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Terminated |
NCT06424236 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05891496 -
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
|
Phase 3 | |
| Terminated |
NCT01733355 -
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
|
Phase 0 | |
| Terminated |
NCT01723488 -
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
|
Phase 0 | |
| Completed |
NCT00911690 -
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|
N/A | |
| Recruiting |
NCT01479855 -
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
|
N/A | |
| Completed |
NCT01469351 -
Identifying Potential Effects of Liraglutide on Degenerative Changes
|
N/A | |
| Completed |
NCT00439010 -
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05269394 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01760005 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
|
Phase 2/Phase 3 | |
| Completed |
NCT04623242 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
|
Phase 2/Phase 3 | |
| Suspended |
NCT05552157 -
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
| Completed |
NCT04023994 -
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT03131453 -
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01946243 -
The Feasibility of Florbetapir Quantitation
|
Phase 4 |